In Vitro Hemodynamic Simulation Testing: Principles, Methods, and Applications for Cardiovascular De

In vitro hemodynamic simulation testing is a laboratory-based evaluation method that replicates physiological blood flow conditions to assess the performance, safety, and hemocompatibility of cardiovascular medical devices such as heart valves, vascular grafts, stents, and blood pumps. Conducted in accordance with internationally recognized standards including ISO 5840, ISO 7198, and ISO 10993-4, this testing provides critical quantitative evidence for regulatory submissions and design optimization. This article presents a comprehensive technical overview of testing samples, evaluation parameters, experimental methods, and practical applications.

Technical Overview

In vitro hemodynamic simulation testing refers to the controlled laboratory reproduction of the human circulatory environment for the purpose of evaluating how medical devices interact with blood flow. By using mock circulatory loops, pulse duplicators, blood-analog fluids, and physiologically representative pressure and flow waveforms, engineers can quantify device performance characteristics before proceeding to animal studies or clinical trials. The methodology bridges the gap between computational modeling and in vivo evaluation, offering reproducible, instrumented, and ethically efficient assessment conditions.

This testing discipline is fundamental to the development and regulatory clearance of cardiovascular implants. Standards organizations such as ISO, ASTM, and national bodies publishing GB standards have established harmonized requirements for hydrodynamic performance assessment, hemocompatibility screening, and durability verification. Key reference documents include ISO 5840-1, ISO 5840-2, and ISO 5840-3 for cardiac valve prostheses, ISO 7198 for vascular prostheses and tubular vascular grafts, ISO 10993-4 for blood-contacting device hemocompatibility, and ASTM F1840 for hemolysis testing terminology. Accredited third-party laboratories routinely perform these evaluations to support submissions to regulatory authorities in major global markets.

The scientific value of in vitro hemodynamic simulation lies in its ability to isolate specific flow phenomena—such as turbulence, recirculation zones, elevated shear stress, and stagnant regions—that correlate with adverse clinical outcomes including hemolysis, thrombosis, restenosis, and structural fatigue. Because test conditions can be precisely controlled and repeated, the method delivers high-fidelity data suitable for statistical comparison, design iteration, and verification against computational fluid dynamics (CFD) predictions.

Testing Samples

Heart Valve Prostheses

Surgical and transcatheter heart valves, including mechanical, bioprosthetic, and polymeric designs, are evaluated for transvalvular pressure gradient, effective orifice area, regurgitant fraction, and leakage volume under pulsatile conditions simulating aortic and mitral positions.

Vascular Grafts, Stents, and Stent-Grafts

Tubular vascular prostheses, bare-metal and drug-eluting stents, and endovascular stent-grafts are assessed for patency-related flow behavior, kink resistance under flow, peri-graft leakage, and wall shear stress distribution in anatomically curved models.

Ventricular Assist Devices and Blood Pumps

Rotary and pulsatile blood pumps, extracorporeal circuits, cannulae, and oxygenator components are tested for hydraulic performance, flow-pressure operating points, and blood damage indices such as normalized index of hemolysis (NIH).

Other Cardiovascular and Blood-Contacting Devices

Sample scope also extends to inferior vena cava filters, septal occluders, embolic protection devices, dialysis access grafts, catheters, extracorporeal membrane oxygenation (ECMO) systems, and artificial heart prototypes.

Testing Items

Evaluation programs are tailored to device type and intended use, and typically include the following parameter categories:

• Hydrodynamic performance: forward flow pressure gradient, reverse flow pressure drop, effective orifice area (EOA), performance index, regurgitant fraction, closing volume, and leakage volume.
• Flow field characterization: velocity mapping, flow jet geometry, turbulence intensity, vortical structures, recirculation and stagnation zones, and particle residence time.
• Shear-related parameters: wall shear stress (WSS), bulk shear stress distribution, and shear exposure time relevant to hemolysis and platelet activation risk.
• Hemocompatibility indicators: plasma free hemoglobin, normalized index of hemolysis, thrombus deposition mass, and platelet count depletion under recirculating blood or blood-analog exposure.
• Physiological waveform compliance: cardiac output range, heart rate sweep, systolic and diastolic pressure simulation, and aortic compliance reproduction.
• Comparative benchmarking: performance quantification of test articles against predicate devices or reference configurations under identical boundary conditions.

Testing Methods

Mock Circulatory Loop and Pulse Duplicator Systems

The core test platform is a mock circulatory loop comprising a pulsatile pump or cam-driven ventricular actuator, compliant chambers representing arterial elasticity, adjustable resistance elements, and fluid reservoirs simulating venous return. Pulse duplicators are configured to reproduce clinically relevant waveforms—typically 70 beats per minute, cardiac outputs from 2 to 7 liters per minute, and physiologic systolic and diastolic pressure targets consistent with ISO 5840-2 test condition requirements.

Working Fluid Selection

Blood-analog fluids are formulated to match the kinematic viscosity of human blood, commonly using glycerin-water mixtures of approximately 36 to 40 percent glycerin by volume for Newtonian analogs. Where non-Newtonian behavior is significant, xanthan gum or polyacrylamide-based analogs may be employed. For hemocompatibility and hemolysis assessment, fresh animal blood—typically bovine or porcine—is used under strictly controlled anticoagulation, temperature, and hematocrit conditions.

Instrumentation and Measurement Techniques

• Calibrated pressure transducers positioned upstream and downstream of the test section record dynamic pressure waveforms for gradient computation.
• Electromagnetic, ultrasonic, or transit-time flow meters quantify instantaneous and mean volumetric flow.
• Particle image velocimetry (PIV) provides planar velocity field mapping with high spatial resolution, using laser sheet illumination and seeded tracer particles.
• Laser Doppler velocimetry (LDV) delivers point-wise velocity measurements with exceptional temporal resolution for turbulence and shear analysis.
• High-speed imaging and echocardiography-compatible configurations capture leaflet or valve motion, opening and closing dynamics, and flow visualization.

Hemolysis and Thrombogenicity Assessment

Blood damage evaluation follows recirculation exposure protocols in which plasma free hemoglobin is sampled at defined intervals and normalized to flow rate and exposure time, yielding the normalized index of hemolysis. Thrombogenicity screening involves macroscopic and gravimetric thrombus quantification on device surfaces following timed blood exposure, supported by flow field analysis identifying low-shear stagnation regions correlated with clot initiation.

Anatomical Model Testing

Silicone or polymer anatomical replicas—produced from medical imaging data—enable evaluation of device behavior under realistic curvature, bifurcation, and compliance conditions, particularly relevant for transcatheter valves, stent-grafts, and cerebral or peripheral vascular devices.

Applications

In vitro hemodynamic simulation testing serves multiple stakeholders across the medical device lifecycle:

• Regulatory submission support: generating performance data packages for premarket notifications, premarket approvals, and conformity assessment under the EU Medical Device Regulation, referencing ISO 5840 series and ISO 7198 requirements.
• Research and development: iterative design optimization of valve leaflet geometry, stent cell architecture, pump impeller profiles, and cannula inlet configurations based on quantified flow performance.
• CFD validation: providing experimental boundary conditions and velocity field data to verify computational fluid dynamics models used in device simulation.
• Comparative device evaluation: head-to-head benchmarking of candidate devices against clinically established predicate products under identical test conditions.
• Durability and wear studies: pulsatile loading integrated with accelerated wear protocols to correlate hydrodynamic performance with long-term structural integrity.
• Academic and clinical research: investigation of disease-state hemodynamics, including stenotic valves, aneurysmal vessels, and heart failure support configurations.

FAQ

What standards govern in vitro hemodynamic simulation testing?

Primary references include ISO 5840-1, 5840-2, and 5840-3 for heart valves, ISO 7198 for vascular prostheses, ISO 10993-4 for hemocompatibility, and ASTM F1840 for hemolysis terminology. Additional ASTM and national GB standards may apply depending on device classification and target markets.

Why are blood-analog fluids used instead of actual blood for flow studies?

Glycerin-based analogs are optically transparent and match blood viscosity, enabling laser-based velocity measurement techniques such as PIV and LDV, which cannot be performed in opaque whole blood. Real blood is reserved for hemolysis and thrombogenicity studies where biological response is the endpoint.

How does in vitro testing complement computational and animal studies?

In vitro experiments provide controlled, repeatable, and instrumented data that validate CFD models, while avoiding biological variability inherent in animal studies. Together, the three methods form a hierarchical verification strategy accepted by regulatory reviewers for demonstrating device safety and performance.

What sample quantities and lead times are typical?

Hydrodynamic performance testing generally requires three to five test articles per configuration to support statistical reporting, with program durations ranging from several weeks for standard evaluations to several months for protocols incorporating durability or blood damage assessment. Exact requirements are defined in the test plan agreed with the accredited third-party laboratory.

Can testing simulate patient-specific pathological conditions?

Yes. Mock circulatory systems can be configured to reproduce hypertensive, hypokinetic, stenotic, or regurgitant circulatory states, and anatomical models can reflect specific patient geometries, enabling worst-case and disease-state scenario evaluation.